Investing in biotechs like CRISPR Therapeutics (NASDAQ: CRSP) can be challenging due to the complexity of assessing management's plans. The upcoming Q3 earnings report will reveal crucial figures related to patient treatments and authorized treatment centers that will impact the company's performance and future prospects.